Form 4: Assembly Biosciences Executive Exercises Stock Options, Sells Shares to Cover Taxes

Nicole S. White, Chief Manufacturing Officer of Assembly Biosciences, exercised stock options and sold shares to cover tax obligations, as reported in a recent SEC filing.

Summary

• Nicole S. White, Chief Manufacturing Officer of Assembly Biosciences, executed a series of transactions involving the company's stock.
• On March 29, 2025, White was granted stock options for 20,400 shares at an exercise price of $10.62.
• These options vest over four years, with 25% vesting on March 29, 2026, and the remaining 75% vesting in monthly installments until March 29, 2029.
• On March 31, 2025, White sold 197 shares of common stock at a weighted average price of $9.8481, ranging from $9.56 to $10.40.
• This sale was to cover tax withholding obligations related to the vesting and settlement of restricted stock units, as mandated by an administrative rule.
• Following these transactions, White directly owns 11,674 shares of Assembly Biosciences common stock and holds options for 20,400 shares.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions related to stock options and tax obligations, indicating a neutral sentiment.

Industry Context

Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to the market regarding their trading activities. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Sell-to-cover transactions are a common practice among publicly traded companies to manage tax obligations related to equity compensation.
• The vesting schedule of the stock options (25% after one year, then monthly) is a fairly standard vesting schedule.
• Comparable companies such as Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated also have executives who regularly file Form 4s for similar transactions.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholders, but the transaction is primarily driven by tax obligations and is not indicative of a change in the executive's long-term outlook on the company.

Key Dates

Keywords

stock options, SEC Form 4, Assembly Biosciences, insider trading, share sale, vesting, ASMB, Nicole S. White